Compared to AML cell lines, MDS cells have a limited proliferative capacity and require exogenous cytokines, like IL-3, GM-CSF, and SCF, which is limiting in vivo studies [8]. This evidence concerns the gene CSF2 and myelodysplastic syndrome.